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Abstract Protein kinase C (PKC) has been implicated to play
an essential function in the upregulation of telomerase activity
in activated T cells, yet its role in the regulation of telomerase
activity remains largely unknown. In this work, we present evi-
dence that PKC activity is required both for the induction of
hTERT expression and for the post-transcriptional control of
telomerase enzyme activity in T lymphocytes. Of the several
PKC isoforms present in lymphocytes, only the level of PKC-
j was greatly increased during T cell activation, implicating that
PKC-j may be required for the post-transcriptional control of
telomerase enzyme activity in T lymphocytes.
& 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Telomerase is a specialized reverse transcriptase that directs
the synthesis of telomeric repeats (TTAGGG in human) at
chromosome ends [1]. Telomerase appears to play a key role
in maintaining telomere length and in replicative senescene.
Normal human somatic cells express low or undetectable te-
lomerase activity and are mortal. In contrast, moderate or
high telomerase activity is present in the majority of immortal
and cancer cells [2,3]. Ectopic expression of telomerase activ-
ity has been shown to extend the life-span of several normal
human cells [4^8]. Together these observations support an
important role of telomerase in cellular immortalization.
The minimal catalytic core of human telomerase consists of
a RNA component (hTER) and of a catalytic protein subunit
(hTERT) with reverse transcriptase activity [9^14]. Additional
telomerase-associated proteins (hTEP1, dyskerin, p23, and
Hsp90) have been identi¢ed [15^18], yet their biochemical
function remains obscure. Studies on the correlation between
telomerase activity and the expression of hTER, hTEP1, and
hTERT have indicated that telomerase activity is strongly
correlated with the abundance of hTERT mRNA [10,11].
The abundance of mRNA for hTEP1 and hTER does not
correlate with telomerase activity [15,16,19]. Together with
the result that ectopic expression of hTERT in somatic cells
is su⁄cient to restore telomerase activity [4^7,12,20], these
observations demonstrate that hTERT is the key regulator
of enzyme activity.
The promoter region of hTERT gene has been character-
ized [21^23]. Sequence analysis has revealed that the hTERT
promoter contains hormone response elements and binding
sites for several transcription factors including cMyc, Spl,
and others [21^23], implicating that hTERT expression may
be regulated by multiple factors. Several activators (cMyc,
Spl) and repressors (WTI, Mad1, E2FI, p53 and MZF-2)
for hTERT expression have been identi¢ed [24,25]. Exactly
how these activators and repressors may function in the di¡er-
ent types of cells to regulate the expression of hTERT remains
largely unknown. While transcriptional regulation of hTERT
gene expression appears to be the primary control of telomer-
ase in human cells, several studies have indicated that protein
phosphorylation can reversibly regulate the function of telo-
merase [26^28]. Protein kinase C (PKC)-K and PKC-j have
been shown to control telomerase activity by phosphorylating
telomerase proteins in breast cancer cells and nasopharyngeal
cancer cells, respectively [27,29].
T lymphocytes require extensive cell division and clonal
expansion for their functions. To achieve this, T lymphocytes
may develop regulatory mechanism to overcome the problem
of replicative senescence. It has been reported that telomerase
activity is expressed and stringently regulated during T lym-
phocyte development and di¡erentiation [30]. Telomerase ac-
tivity is low or undetectable in peripheral T lymphocytes, but
is upregulated several hundred-fold upon activation [30,31].
The expression of telomerase activity in activated T lympho-
cytes has been known to require PKC-dependent activity
[32,33]. Exactly how PKC functions to upregulate telomerase
activity during T cell activation is not known, however. In this
work, we investigate if the expression of telomerase activity in
activated T cells is mediated by the PKC-dependent transcrip-
tional induction of hTERT expression or by the PKC-depen-
dent post-transcriptional control of enzyme activity, or both.
2. Materials and methods
2.1. Chemicals, enzymes, antibodies, and oligonucleotides
RPMI medium 1640, Hanks’ balanced salt solution (HBSS), Super-
script II reverse transcriptase, TRIzol reagent, antibiotics, and phyto-
hemagglutinin (PHA) were purchased from Gibco-BRL. RNase inhib-
itor, bisindolylmaleimide I (BIM 1), and Go«6976 were purchased from
CalBiochem. Co., San Diego, CA, USA. Taq DNA polymerase was
from Viogene Co., Taipei, Taiwan. Antibodies against individual
PKC isoform and secondary antibody were from Santa Cruz Biotech.
The sequence and source of TS, CX, LT5, LT6, K136 and K137
oligonucleotides were previously described [29]. Gel electrophoresis
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reagents were from Bio-Rad. All other chemicals were from Sigma
Chemical Co.
2.2. Cell culture
Blood was collected in heparinized tubes, and mononuclear cells
were isolated by density gradient centrifugation using Ficoll-Hypaque
(Ficoll-Paque, Pharmacia Biotech. Co., Uppsala, Sweden). These pe-
ripheral blood mononuclear cells were cultured in RPMI medium
1640 containing 20% fetal bovine serum and antibiotics (100 U/ml
penicillin, 100 U/ml streptomycin and 0.25 Wg/ml amphotericin B)
for 24 h. Floating cells were collected and used as the source of
peripheral blood lymphocytes (PBL). PBL were cultured at a density
of 1U106 cells/ml in RPMI medium 1640 using 24-well plates. When
required, PHA, BIM I, and Go«6976 were added at 1:50, 5 mM, and
2.5 mM, respectively. Cells were grown at 37‡C in a humidi¢ed in-
cubator containing 5% CO2.
2.3. Telomerase activity assay
Cell extracts were obtained as described [34]. A polymerase chain
reaction (PCR)-based telomeric repeat ampli¢cation protocol (TRAP)
[2] was used for assaying telomerase activity. The condition for PCR
ampli¢cation and analysis of PCR products by electrophoresis on
polyacrylamide gel was as described [34].
2.4. Determination of hTERT mRNA expression by reverse
transcriptase PCR
Total RNA was extracted by TRIzol isolation reagent following
manufacturer’s instruction. The primers used were: LT5 and LT6
for hTERT, and K136 and K137 for GAPDH. The condition for
reverse transcriptase PCR for hTERT mRNA was predetermined
with serial dilutions of total RNA such that the amount of RNA
used in the reaction was in the linear range of the assay. In brief,
reverse transcription was performed by addition of 30 ng of total
RNA, 10 pmol of each primer, 4 U of reverse transcriptase, 10 U
of RNase inhibitor, and 2 U of Taq polymerase to a 30 Wl of bu¡er
containing 20 mM Tris, pH 8.2, 50 mM KCl, 0.25 mM dNTPs, 0.1%
bovine serum albumin, and 1 mM MgCl2. The reaction mixtures were
incubated at 42‡C for 1 h, followed by heat inactivation at 94‡C for
3 min. PCR ampli¢cation was carried out by 31 cycles of denaturation
at 94‡C for 45 s, annealing at 60‡C for 45 s, and extension at 72‡C for
1.5 min. The PCR products were separated by electrophoresis in 5 or
8% polyacrylamide gels and analyzed as described [29].
2.5. Western blot analysis of PKC isoforms
Western blot analysis was performed as previously described [29].
3. Results
3.1. PKC is required for the induction of hTERT expression
Since hTERT appears to be the key regulator of telomerase
activity and is known to be upregulated during T cell activa-
tion [31], our ¢rst question is to address if PKC activity is
required for the induction of hTERT expression. PBL were
treated with PHA to stimulate T lymphocyte proliferation and
the expression of hTERT and telomerase activity was fol-
lowed. As shown in Fig. 1, an increase of hTERT mRNA
was detectable as early as 6 h after the addition of PHA to
the cells. Expression of hTERT peaked at 1^2 days and then
slowly decreased to the basal level. The expression of telomer-
ase activity began to increase after about 12^18 h and peaked
at 2^3 days following the addition of PHA to the cells. After
3 days, telomerase activity began to level o¡ and then de-
creased slowly. In the absence of PHA, there was no detect-
able increase of telomerase activity or hTERT RNA expres-
sion over 2 days (data not shown). These results are in general
agreement with the results obtained by others that the expres-
sion of telomerase activity in activated T cells is accompanied
with the induction of hTERT expression [31].
To explore if PKC activity is required for the induced ex-
pression of hTERT, the e¡ects of PKC inhibitors on the ex-
pression of telomerase activity and hTERT were examined in
PHA-treated PBL. As shown in Fig. 2, the increased expres-
sion of hTERT and telomerase activity was completely inhib-
ited when PKC inhibitor (BIM I or Go«6976) was added si-
multaneously with the PHA, indicating that the induced
expression of hTERT requires PKC activity.
3.2. PKC is also required for post-transcriptional control of
telomerase activity
In view of the reports that protein phosphorylation can
reversibly regulate the function of telomerase [26^29], we
ask if PKC activity is also required for post-transcriptional
control of telomerase enzyme activity. PBL were treated with









0   0.25   0.5   0.75   1     2     3      4       5      6      7
0   0.25 0.5  0.75   1    2    3    4     5   6     7
Fig. 1. Kinetics of hTERT expression and telomerase activation in
PHA-treated PBL. PBL were treated with PHA for the indicated
times and assayed for the expression of hTERT mRNA and telo-
merase activity as described in Section 2. The expression of
GAPDH mRNA, served as a control, was also included. Lane P is
a positive control using cell extract obtained from telomerase-posi-
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Fig. 2. E¡ect of BIM I and Go«6976 on the expression of hTERT
and telomerase activity in PHA-treated PBL. PBL were treated with
PHA and PKC inhibitor (BIM I or Go«6976) simultaneously for the
indicated times and assayed for the expression of hTERT mRNA
and telomerase activity as described in Section 2. Panels: A, no in-
hibitor; B, plus BIM 1; C, plus Go«6976.
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were then added to examine their e¡ects on the expression of
telomerase activity. As shown in Fig. 3, when PKC inhibitors
were added 6 or 12 h after PHA addition, telomerase activity
was not activated in the following days. However, the hTERT
mRNA was readily detectable at these times and continued to
be expressed in the following days (Fig. 4). When PKC inhib-
itors were added 24 h after PHA addition, telomerase activity
was not further increased. Instead, the telomerase activity was
reduced in the following days (Fig. 3). Accompanied with the
decrease of telomerase activity, the expression of hTERT
mRNA was also reduced (Fig. 4).
3.3. Level of individual PKC isoforms in PHA-treated
lymphocytes
Since speci¢c PKC isoform is employed by di¡erent cancer
cells to control telomerase activity in vivo [27,29], we seek to
understand which PKC isoform(s) may participate in the con-
trol of telomerase activity in lymphocytes. The level of PKC
isoforms was monitored by Western blot during T cell activa-
tion and the results are shown in Fig. 5. The level of PKC-K,
-L1, -N, or -O was little changed after the PHA-stimulation. In
contrast, the expression of PKC-j was greatly increased. A
signi¢cant increase of PKC-j began to be detected at about
18 h after PHA addition, which coincided with the increased
expression of telomerase activity seen in Fig. 1.
4. Discussion
Possible involvement of PKC in the upregulation of telo-
merase activity in activated T cells may include: (i) phosphor-
ylation of telomerase proteins, (ii) increased expression of te-
lomerase genes through PKC-dependent signal pathway, and
(iii) both of the above postulates. In this work, we have pre-
sented evidence to indicate that the increased expression of
telomerase activity during T cell activation requires PKC-de-
pendent activity to induce the expression of hTERT. It is
likely that the early induction of hTERT expression during
T cell activation is mediated through PKC-dependent signal
pathway to induce the expression of cMyc, since it is known
that cMyc is one of the earlier genes that are induced follow-
ing T cell activation [35] and that overexpression of cMyc is
able to induce the expression of hTERT [36^38]. Activation of
pre-existing PKC isoforms is likely to account for the induced
expression of hTERT. Rapid translocation of speci¢c PKC
isoforms to membrane has been observed in T cells stimulated
to proliferate by various agents [39]. At present, it is not yet
possible to correlate the activation of any speci¢c PKC iso-
form(s) with the induction of hTERT.
In addition to a role in the induction of hTERT expression,
PKC-dependent activity is also required for the post-tran-
scriptional control of telomerase enzyme activity in T lympho-
cytes. Such a conclusion is based on the observations that no
activation of telomerase activity was observed when PKC in-
hibitors were added at 6 or 12 h after PHA treatment (Fig. 3).
Under this condition, the expression of hTERT mRNA was
either little changed or continued to increase in the following
A
B
Fig. 3. E¡ect of delayed addition of PKC inhibitors on the telomer-
ase activity of PHA-treated PBL. PBL were treated with PHA and
PKC inhibitor (BIM I or Go«6976) was then added at the indicated
times. Telomerase activity was assayed by TRAP as described in
Section 2. Panels: A, plus BIM 1; B, plus Go«6976.
A
B
Fig. 4. E¡ect of delayed addition of PKC inhibitors on the expres-
sion of hTERT in PHA-treated PBL PBL were treated with PHA
and PKC inhibitor (BIM I or Go«6976) was then added at the indi-
cated times. The expression of hTERT mRNA was assayed by re-
verse transcriptase PCR as described in Section 2. Lane P is a posi-
tive control using cell extract obtained from telomerase-positive HL-
60 cells. Lane N is a negative control with no cell extract. Panels:
A, plus BIM 1; B, plus Go«6976.
Time (Days)







Fig. 5. Level of PKC isoforms in PHA-treated PBL. PBL were
treated with PHA and cultured for the indicated times. The level of
PKC isoforms was monitored by Western blot as described in Sec-
tion 2. The level of actin, served as an internal control, was in-
cluded.
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days (Fig. 4). The lack of activated telomerase activity in the
presence of hTERT expression suggests that PKC activity is
also required for the post-transcriptional control of telomer-
ase. A role of PKC in the control of telomerase activity has
been demonstrated to phosphorylate telomerase proteins [26^
29]. We suggest that PKC also participates in the phosphor-
ylation of telomerase proteins in T lymphocytes.
A non-transcriptional mechanism of regulating telomerase
has also been described previously for CD4þ T cells activated
by anti-CD3 [40]. Phosphorylation of hTERT protein was
observed and is thought to account for the increased telomer-
ase activity under this condition. It is likely that PKC partic-
ipates in the phosphorylation of hTERT during this activation
event, although de¢nitive proof of such a postulate awaits
further con¢rmation.
While the delayed addition of PKC inhibitors did not ap-
pear to inhibit the expression of hTERT in PBL treated with
PHA for 6^12 h, an inhibition of hTERT expression was
observed in PBL treated with PHA for 24 h (Fig. 4). Although
it is possible that T lymphocytes activated for di¡erent lengths
of time may employ di¡erent mechanism to express hTERT
and therefore, display di¡erential sensitivity to the inhibition
by PKC inhibitors. At present, we are at a loss trying to
understand these puzzling data.
Finally, we have attempted to understand which PKC iso-
form participates in the post-transcriptional control of telo-
merase activity. Among the several PKC isoforms detected in
lymphocytes, only PKC-j is greatly increased following PHA
stimulation (Fig. 5). The increased expression of PKC-j ap-
pears to coincide with the increase of telomerase activity. This
result plus the fact that the expression of telomerase activity
was considerably lagged behind the induction of hTERT (Fig.
1) suggest that the post-transcriptional control of enzyme ac-
tivity probably does not employ the pre-existing PKC iso-
forms, rather, the increased PKC-j may be required to per-
form such an function. However, the inhibition of telomerase
activity by Go«6976 (Fig. 3B) casts some doubts about the
validity of this deduction. This drug is known to be relative
speci¢c for inhibiting calcium-dependent PKC isoforms
(PKC-K, -L, and -Q) in vitro [41]. If such a speci¢c inhibition
also occurs in the treated cells, the observed inhibition of
telomerase by this drug would argue that the calcium-depen-
dent PKCs are also involved in the control of telomerase
activity. Perhaps, the post-transcriptional control of telomer-
ase activity in T lymphocytes may require the coordinated
action of several PKC isoforms. Attempts to speci¢cally in-
hibit individual PKC isoform during T cell activation using
antisense oligonucleotides were unsuccessful, because these
primary cells were refractory to DNA transfection. Therefore,
while our data are consistent with a role of PKC-j in the post-
translational control of telomerase activity, we can not ex-
clude the possibility that other PKC isoform(s) also partici-
pates in the post-transcriptional control of telomerase activity
in T lymphocytes.
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